Trial Profile
A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel; Zoledronic acid
- Indications Bone metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 31 May 2020 Results (N=10), presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 14 Jan 2018 Status changed from not yet recruiting to recruiting.
- 04 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 May 2017.